A study looked at how different medications affect patients who have both atrial fibrillation and drug-eluting stents. Researchers compared using one medication (NOAC monotherapy, such as apixaban or rivaroxaban) against a combination of a NOAC plus clopidogrel. The study included 960 patients over a one-year period.
The results showed that for patients aged 75 and older, the single medication group had a much lower rate of major clinical events compared to those on combination therapy. Specifically, the risk was 9.8% in the monotherapy group versus 22.3% in the combination group. For patients under age 75, there was no significant difference between the two treatment methods.
While the study suggests a benefit for older patients, it is important to note that this was a post hoc analysis. This means the researchers looked at data after the trial was completed rather than testing this specific comparison from the start. Because of this, the findings should be viewed as an association rather than a definitive proof of cause. Patients should talk to their doctors about how these results apply to their specific health needs.
